Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Study sponsor: Vanda Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-05-22Actual
Enrollment · participants47Actual
Source updated2025-09-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.